Price
CHART BY
Frequently asked questions
What is XOMA's market capitalization?
The market capitalization of XOMA is $277.13M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for XOMA?
XOMA's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$3.477. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for XOMA's stock?
Currently, 3 analysts cover XOMA's stock, with a consensus target price of $79.50. Analyst ratings provide insights into the stock's expected performance.
What is XOMA's revenue over the trailing twelve months?
Over the trailing twelve months, XOMA reported a revenue of $21.61M.
What is the EBITDA for XOMA?
XOMA's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$15.17M. EBITDA measures the company's overall financial performance.
What is the free cash flow of XOMA?
XOMA has a free cash flow of -$15.55M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does XOMA have, and what sector and industry does it belong to?
XOMA employs approximately 13 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of XOMA's shares?
The free float of XOMA is 11.68M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $277.13M
- EPS (TTM)
- -$3.477
- Free Float
- 11.68M
- Revenue (TTM)
- $21.61M
- EBITDA (TTM)
- -$15.17M
- Free Cashflow (TTM)
- -$15.55M
Pricing
- 1D span
- $23.54$25.16
- 52W span
- $21.72$34.78
Analyst Ratings
The price target is $79.50 and the stock is covered by 3 analysts.
Buy
2
Hold
1
Sell
0
Information
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
- Employees
- 13
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US98419J2069
- Primary Ticker
- XOMA
Knockouts
Finance data from FactSet